Clinical trial
Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
NCT00440648 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00440648 |
|---|---|
| Title | Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate |
| Official title | A Double-Blind, Cross-Over Design Study of Sevelamer Hydrochloride (Renagel®) and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | sevelamer carbonate, sevelamer hydrochloride |
| Enrollment | 80 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Feb 27, 2007 |
| Last update posted | Mar 19, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: